结合压缩和冷却疗法用于Taxane化疗诱导的周围神经病变在肺癌中
Yasuhiro Nakajima1,2, Kozo Kuribayashi3, Akio Tada1,2
1Division of Respiratory Medicine, Department of Internal Medicine, Society of St. Franciscan Himeji St. Mary's Hospital, Himeji, Japan.
Anticancer research
|September 26, 2025
概括
联合压缩和冷却疗法有效地预防化学疗法诱导的周围神经病变 (CIPN) 在接受纳税的肺癌患者. 这种非药物治疗方法显示轻度神经病变的发病率很低,没有报告严重病例.
科学领域:
- 在瘤学瘤学.
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 化疗诱导的周围神经病变 (CIPN) 是高类化疗的常见,致残的副作用.
- 接受纳税剂的肺癌患者患有CIPN的风险很高.
- 对CIPN有效的预防策略对于维持治疗坚持和生活质量至关重要.
研究的目的:
- 评估联合压缩和冷却疗法的有效性,以预防CIPN.
- 评估这种非药物干预的安全性和可行性.
- 为了确定这种疗法的影响,对纳治疗的肺癌患者.
主要方法:
- 追溯分析了53名接受基于税的化疗的晚期肺癌患者.
- 在输液过程中实施联合压缩 (手术手套,弹性) 和冷却 (冰枕).
- 监测CIPN发生率,严重程度和治疗修改.
主要成果:
- 观察到CIPN的总体发病率较低 (20.8%).
- 没有患者出现≥3级神经病变;帕克利塔塞尔和纳布-帕克利塔塞尔疗法显示较低的CIPN比多塞塔塞尔.
- 治疗耐受性良好,有轻度,可逆的不良事件,没有减少化疗剂量.
结论:
- 联合压缩和冷却疗法是预防肺癌患者CIPN的安全和可行的非药物选择.
- 这种方法可能有助于减轻纳素化疗的常见副作用.
- 建议进行进一步的前性研究来验证这些发现.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
672
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
672
Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
462
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
462


